Premium
URINARY INFECTIONS: RESULTS OF TREATMENT WITH COMPOSITE LONG‐ACTING SULPHONAMIDE (DOSULFIN)
Author(s) -
Sutherland J. W.
Publication year - 1965
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1965.tb09667.x
Subject(s) - urinary system , medicine , urine , cure rate , surgery
SUMMARY1 The investigation surveys the progress of 210 patients treated for urinary tract infections which were sensitive to sulphonamide, with the composite long‐acting sulphonamide Dosulfin (Geigy). 2 Three groups of clinical infection were recognised according to the chronicity of the infection and the presence or absence of any underlying urological condition. The numbers in the three groups were approximately equal. 3 Clinical details studied included age, sex, length of symptoms, urological diagnosis, radiological, cystoscopic, and bacteriological findings. The diversity of conditions encountered made the test of the therapeutic agent employed a fairly stringent one, even although the infection was sensitive to it. 4 Success was regarded as being the eradication of both the symptoms and the pus cells and organisms from the urine. This was achieved in over 60 per cent, of all cases treated with Dosulfin and in over 80 per cent, of Group I cases (early infections). Uncomplicated urinary infections responded therefore quite satisfactorily. Results were poorer in Groups II and III. Females seemed to respond slightly better than males. 5 In a smaller group of 51 patients followed for longer periods, 70 per cent, did not relapse when observed over periods ranging from four to fifteen months. 6 Previous investigations suggest that there is a natural cure rate, and to prove themselves of real value any new compounds must clearly produce better results than this rate. 7 Long‐acting composite sulphonamide fulfils fairly well most of the conditions laid down for the perfect therapeutic agent for urinary infections apart from the possession of broad‐spectrum activity. This apart, the newer sulphonamides merit more attention than they are receiving and a return to their use on a wider scale is obviously overdue. 8 Urinary infections are potentially dangerous as well as disturbing to patients. They are the commonest of all urological conditions and in many ways the least well understood. Nothing could be further from the truth than to say that the subject is simply a matter of determining sensitivities and carrying on mechanically from there.